The Parachute® Implant System is a ventricular partitioning device developed by Cardiokinetix Inc. It is used to isolate damaged heart muscle in patients with symptoms of heart failure due to ischaemic heart disease.
After a heart attack, the damaged heart muscle can become over stretched as it has less resistance than undamaged muscle and is unable to contract. The left ventricle in the heart then enlarges as healthy muscle tries to compensate for lost function. This progressive enlargement eventually overloads the heart, causing a decrease in cardiac output and resulting in symptoms of heart failure such as fatigue, shortness of breath and fluid accumulation.
Tezepelumab is a monoclonal antibody (protein) that targets proteins early in the inflammatory cascade. By targeting proteins early in the inflammatory cascade, several downstream inflammatory proteins are suppressed, thereby decreasing inflammation. Tezepelumab given as an add-on-therapy to patients with severe uncontrolled asthma has been shown to be safe, well tolerated, and effective. Tezepelumab is administered subcutaneously. If licensed, tezepelumab as an add on therapy would offer an additional biological therapy to those over 12 years old, with severe asthma.